Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia is a research paper published in Leukemia (2021). On theSindex it has a DataRank of 0.483. It has been cited 24 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →U.S. Department of Health & Human Services | NIH | National Cancer Institute
Grant: 600897
National Institutes of Health
Grant: 5R21CA229961-02
Validation of Siglec-6 as a novel target for cancer immunotherapy
NCI NIH HHS
Grant: R21 CA229961
Intramural NIH HHS
Grant: Z99 CA999999
FWCI
1.46
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals